Chemotherapy of human malignant glioma: Prevention of efficacy by dexamethasone?

Neurology

Volumn 48, Issue 6, 1997, Pages 1704-1709

  Weller, Michael ^a   Schmidt, Christine ^a   Roth, Wilfried ^a   Dichgans, Johannes ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; NIMUSTINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TENIPOSIDE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL PROTECTION; COLONY FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0030859359     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.6.1704     Document Type: Article

References (27)

1. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71:2585-2597.
2. Lesser GJ, Grossman S. The chemotherapy of high-grade astrocytomas. Semin Oncol 1994;21:220-235.
3. Koehler PJ. Use of corticosteroids in neuro-oncology. Anticancer Drugs 1995;6:19-33.
4. Crocker EF, Zimmerman RA, Phelps ME, Kuhl DE. The effect of steroids on the extravascular distribution of radiographic contrast material and technetium pertechnetate in brain tumors as detected by computed tomography. Radiology 1976; 119:471-474.
5. Neuwelt EA, Barnett PA, Bigner DD, Frenkel EP. Effects of adrenal cortical steroids and osmotic blood-brain barner opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci USA 1982;79:4420-4423.
6. Hatam A, Bergström M, Yu ZY, Granholm L, Berggren BM. Effect of dexamethasone treatment on volume and contrast enhancement of intracranial neoplasms. J Comput Assist Tomogr 1983;7:295-300.
7. Müller W, Kretzschmar K, Schicketanz KH. CT-analyses of cerebral tumors under steroid therapy. Neuroradiology 1984; 26:293-298.
8. Cairncross JG, Macdonald DR, Pexman JHW, Ives FJ. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 1988;38:724-726.
9. Watling CJ, Lee DH, Macdonald DR, Cairncross JG. Steroid-induced MR changes in patients with recurrent malignant glioma. J Clin Oncol 1994;12:1886-1889.
10. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013-2026.
11. Martin SJ, Green DR. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol 1995;18:137-153.
12. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human malignant glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 1994;94:954-964.
13. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.
14. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-1805.
15. Alderson LM, Castleberg RL, Harsh GR, Louis DN, Henson JW. Human gliomas with wild-type p53 express bcl-2. Cancer Res 1995;55:999-1001.
16. Weller M, Malipiero UV, Aguzzi A, Reed JC, Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995;95:2633-2643.
17. Weller M, Malipiero U, Rensing-Ehl A, Barr P, Fontana A. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 1995;55:2936-2944.
18. Roth W, Fontana A, Trepel M, Reed JC, Dichgans J, Weller M. Synergistic cytotoxicity of malignant glioma cells induced by CD95 ligand and cytotoxic drugs. J Neurooncol 1996;30: 102.
19. Van Meir EG, Kikuchi T, Tada M, et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 1994;54:649-652.
20. Wolff JEA, Jürgens H. Dexamethasone induced partial resistance to methotrexate in C6-glioma cells. Anticancer Res 1994;14:1585-1588.
21. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995;9:451-473.
22. Begg EJ, Atkinson HC, Gianarakis N. The pharmacokinetics of corticosteroid agents. Med J Aust 1987;146:37-41.
23. Brophy TRO, McCafferty J, Tyrer JH, Eadie MJ. Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. Eur J Clin Pharmacol 1983;24:103-108.
24. Richter O, Ern B, Reinhardt D, Becker B. Pharmacokinetics of dexamethasone in children. Ped Pharmacol 1983;3:329-337.
25. Rohdewald P, Möllmann H, Earth J, Rehder J, Derendorf H. Pharmacokinetics of dexamethasone and its phosphate ester. Biopharm Drug Dispos 1987;8:205-212.
26. Berndt SF, Fuhrmeister U. Cerebrospinal fluid levels of cortisol, prednisone and dexamethasone following intravenous and intrathecal injection in man. Naunyn Schmiedebergs Arch Pharmacol 1973;279(Suppl):R51.
27. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983;67:121-132.